Knowledge Tree
Relations (1)
related 3.58 — strongly supporting 11 facts
MDMA is being investigated as a therapeutic intervention for PTSD, as evidenced by clinical trials conducted by MAPS {fact:1, fact:6} and research into its efficacy as a psychotherapeutic tool {fact:8, fact:11}. The potential for MDMA-assisted therapy to treat PTSD has been the subject of significant study, including phase 2 and phase 3 clinical trials {fact:7, fact:10} and individual patient accounts {fact:2, fact:5}.
Facts (11)
Sources
Effects of psychedelics on neurogenesis and broader neuroplasticity link.springer.com 5 facts
claimMDMA is being explored as a treatment for post-traumatic stress disorder (PTSD) under controlled dosing regimens.
claimSessa B published research in 2017 regarding the use of MDMA in the treatment of PTSD, framing it as an innovative therapeutic approach.
referenceMithoefer et al. (2019) published a study in Psychopharmacology outlining the study design and rationale for phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD, based on a pooled analysis of six phase 2 randomized controlled trials.
accountPsychopharmacologist Alexander Shulgin synthesized MDMA in the 1970s and, following self-experimentation, proposed its use as a medicine to assist patients in therapy for PTSD and addiction disorders.
claimMDMA is currently in the final stages of clinical research for approval as a psychotherapeutic tool for the treatment of PTSD.
History and Current Status of Psychedelics and Entactogens ... - NCBI ncbi.nlm.nih.gov 4 facts
accountIn 2017, Lori Tipton participated in a Multidisciplinary Association for Psychedelic Studies (MAPS) clinical trial exploring the use of MDMA for the treatment of PTSD.
accountTipton completed the MDMA-assisted therapy trial in 2018 and reported that she no longer qualified for a PTSD diagnosis, a status she maintained as of the time of the interview.
referenceThe MAPS Phase 3 MDMA-Assisted Therapy for PTSD study is a clinical trial investigating the use of MDMA for treating PTSD.
quoteTipton described her MDMA-assisted therapy sessions as 'very interesting and intense' and noted that the experience allowed her to feel embodied in a way she had not felt in years due to PTSD.
Neuroimaging in psychedelic drug development: past, present, and ... nature.com 1 fact
claimEarly clinical trial work in the mid-2000s tested the efficacy of MDMA in treating post-traumatic stress disorder.
What Western medicine can learn from the ancient history of ... - BBC bbc.com 1 fact
accountOn 10 August 2024, the US Food and Drug Administration (FDA) announced it would not approve MDMA-assisted therapy as a treatment for moderate to severe post-traumatic stress disorder (PTSD), citing insufficient data to conclude the drug was safe and effective, despite promising results from a Phase 3 trial published in September 2023.